Figure 1.

Tumor growth after bevacizumab treatment. After placement of B16F10 melanoma cells in the eye of C57Bl/6 mice, bevacizumab was injected intraocularly to try to inhibit intraocular tumor growth. Following three bevacizumab injections on days 2, 6, and 10, a significant acceleration of intraocular tumor growth occurred compared to the control group (AVA1 versus control p=0.007, and AVA10 versus control p=0.06). Growth was recorded as the percentage of anterior chamber occupied with tumor, and mice were sacrificed when the tumor occupied 80%–100% of the anterior chamber. The curves are the pooled data from two experiments, with 14 mice in each of the three groups. AVA1=equivalent human dose: 2 μg/4 µl; AVA10=10 times the equivalent human dose: 20 μg/4 μl; CO=control group: 4 µl mock PBS injection.